Publications by authors named "K Ronan"
Article Synopsis
- Genomic understanding of urothelial carcinoma is growing, revealing high mutation rates and genetic changes, prompting research into effective therapies for better patient outcomes.!
- This study aimed to determine the frequency of next-generation sequencing (NGS) and identify genomic alterations in Irish patients with metastatic urothelial cancer (mUC) between 2017 and 2022.!
- Among 111 mUC patients, NGS was performed on 66, revealing 36 targetable alterations, with common therapies including erdafitinib and trastuzumab; targeted therapy was administered to 13.5% of patients with a median treatment duration of 3 months.!
Resource utilization and convalescent care cost in neonatal opioid withdrawal syndrome.
J Neonatal Perinatal Med
April 2023
Background: Neonatal opioid withdrawal syndrome (NOWS) is a growing public health problem associated with complex and prolonged medical care and a significant resource utilization burden. The objective of this study was to compare the cost of different convalescent care settings for infants with NOWS.
Methods: Retrospective comparison study of infants with NOWS discharged directly from NICU, transferred to an acute care pediatric floor (PPCU) or rehabilitation hospital (PRH).
Article Synopsis
- - Immune checkpoint inhibitors are advanced cancer therapies that help more than one-third of patients but are effective in less than 40% of cases, often leading to autoimmune side effects.
- - Current approved biomarkers for treatment eligibility, like PD-L1 expression and tumor mutational burden, lack precision and are not highly sensitive.
- - The review explores new potential biomarkers, including advanced immunohistochemistry scores and the role of the gut microbiome in influencing treatment success and side effects.
Background: Enzalutamide is part of the treatment regimen for metastatic castration-resistant prostate cancer (MCRPC). However, both intrinsic and acquired resistance to the drug remain substantial clinical quandaries. circRNAs, a novel type of non-coding RNA, have been identified in a number of cancers including prostate cancer and have been associated with cancer development and progression.
View Article and Find Full Text PDFLung cancer is a leading cause of cancer-related deaths, contributing to 18.4% of cancer deaths globally. Treatment of non-small cell lung carcinoma has seen rapid progression with targeted therapies tailored to specific genetic drivers.
View Article and Find Full Text PDF